Application No. 10/618,298
Reply dated January 8, 2007
Reply to July 7, 2006 Restriction Requirement

REMARKS

The Examiner requires restriction of pending claims 1101 under 35 U.S.C. § 121, between the following patentably
distinct species of inventions:

- A) Antibody;
- B) CD40 ligand;
- C) CD40;
- D) nonprotein;
- E) library of known agents;
- F) modified from a known agent;
- G) small molecule.

Applicants elect the Species A (antibodies), with traverse, for substantive examination in this application. The claims reading on species A include claims: 1-13, 21-23, 25-29, 38-56, 65-69, 75, 78-97 and 98-101.

The Examiner also requires applicants to elect one of the following patentably distinct species of indications:

- (A) arthritis;
- (B) scleroderma;
- (C) fibrosis;
- (D) atherosclerosis;
- (E) reperfusion injury;
- (F) allograft rejection, organ rejection;
- (G) multiple sclerosis;
- (H) vasculitis;
- (I) psoriasis; or
- (J) myeloma.

Application No. 10/618,298
Reply dated January 8, 2007
Reply to July 7, 2006 Restriction Requirement

In response, applicants elect species (H): vasculitis. The claims reading on this species include claims: 1-78, 92-93 and 95-96.

Applicants make the foregoing elections expressly without waiver of their rights: (1) to file for and obtain claims directed to non-elected subject matter in one or more patent applications claiming priority herefrom under 35 U.S.C. § 120 and (2) subject to allowance of a generic claim, to rejoin other claims depending therefrom or otherwise including all the limitations of the allowable generic claim.

Applicants request favorable consideration and allowance of this application.

Respectfully submitted,

Margaret A Pierri (Reg. No. 30,709) Stanley D. Liang (Reg. No. 43,753)

Attorneys for Applicants

FISH & NEAVE IP GROUP

ROPES & GRAY LLP

Customer No. 1473

1251 Avenue of the Americas

New York, New York 10020-1104

Tel.: (212) 596-9000 Fax: (212) 596-9090